109 related articles for article (PubMed ID: 30535536)
1. A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Duska LR; Petroni GR; Lothamer H; Faust W; Beumer JH; Christner SM; Mills AM; Fracasso PM; Parsons SJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):473-482. PubMed ID: 30535536
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Ishida Y; Murai K; Yamaguchi K; Miyagishima T; Shindo M; Ogawa K; Nagashima T; Sato S; Watanabe R; Yamamoto S; Hirose T; Saitou S; Yonezumi M; Kondo T; Kato Y; Mochizuki N; Ohno K; Kishino S; Kubo K; Oyake T; Ito S;
Eur J Clin Pharmacol; 2016 Feb; 72(2):185-93. PubMed ID: 26507546
[TBL] [Abstract][Full Text] [Related]
4. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
6. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
7. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.
Hahn NM; Knudsen BS; Daneshmand S; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Liu Z; Breen T; Fleming MT; Lance R; Corless CL; Alva AS; Shen SS; Huang F; Gertych A; Gallick GE; Mallick J; Ryan C; Galsky MD; Lerner SP; Posadas EM; Sonpavde G
Urol Oncol; 2016 Jan; 34(1):4.e11-7. PubMed ID: 26362343
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
[TBL] [Abstract][Full Text] [Related]
11. [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
Wang Z; Li L; Shao Z; Xie H; Yang F; Zhou N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):595-9. PubMed ID: 27126935
[TBL] [Abstract][Full Text] [Related]
12. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
Choi KM; Cho E; Bang G; Lee SJ; Kim B; Kim JH; Park SG; Han EH; Chung YH; Kim JY; Kim E; Kim JY
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291786
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
14. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Kelley MJ; Jha G; Shoemaker D; Herndon JE; Gu L; Barry WT; Crawford J; Ready N
Cancer Invest; 2017 Jan; 35(1):32-35. PubMed ID: 27911119
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
Chen B; Xu X; Luo J; Wang H; Zhou S
PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
